SCHEMBL4089307

SCHEMBL4089307

CC(C)n1cc(C(=O)c2cccc(NC(=O)Nc3cccc(C(F)(F)F)c3)n2)c2c(N)ncnc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.61
PDPK1 O15530 4/20 0.52
RET P07949 5/20 0.51
NTRK1 P04629 2/20 0.49
NTRK2 Q16620 2/20 0.49
NTRK3 Q16288 1/20 0.49
LCK P06239 3/20 0.48
SRC P12931 3/20 0.48
KDR P35968 4/20 0.47
FLT1 P17948 3/20 0.47
TEK Q02763 3/20 0.47
AURKA O14965 2/20 0.47
AURKB Q96GD4 2/20 0.47
KIT P10721 2/20 0.47
FLT3 P36888 2/20 0.47
DCLK1 O15075 1/20 0.47
DYRK3 O43781 1/20 0.47
ROCK2 O75116 1/20 0.47
MAP4K4 O95819 1/20 0.47
CHEK2 O96017 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4089428 0.90 PDGFRB (0.63) PDGFRBPDPK1RETNTRK1NTRK2
SCHEMBL4083225 0.89 PDGFRB (0.60) PDGFRBPDPK1RETNTRK1NTRK2
SCHEMBL4083193 0.89 PDGFRB (0.64) PDGFRBPDPK1RETNTRK1NTRK2
SCHEMBL4076422 0.88 PDGFRB (0.71) PDGFRBPDPK1RETNTRK1NTRK2
SCHEMBL4076329 0.86 PDGFRB (0.63) PDGFRBPDPK1RETNTRK1NTRK2
SCHEMBL4081244 0.85 PDGFRB (0.74) PDGFRBPDPK1RETNTRK1NTRK2
SCHEMBL4079876 0.84 PDGFRB (0.65) PDGFRBPDPK1NTRK1NTRK2NTRK3
SCHEMBL1940859 0.84 PDGFRB (0.63) PDGFRBRETNTRK1NTRK2NTRK3
SCHEMBL4076616 0.83 NTRK1 (0.61) PDGFRBPDPK1RETNTRK1NTRK2
SCHEMBL4088005 0.82 NTRK1 (0.73) PDGFRBPDPK1RETNTRK1NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595325-B2 Substituted pyrrolo[2,3-d]pyrimidine derivatives useful in cancer treatment PFIZER INC. (US) 2009-09-29 US disclosed
EP-1773836-A1 PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT Pfizer Products Inc. (US) 2007-04-18 EP disclosed
US-20060035912-A1 Pyrrolopyrimidine derivatives useful in cancer treatment PFIZER INC 2006-02-16 US disclosed
WO-2005116035-A1 PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT PFIZER PRODUCTS INC. (US) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035912-A1 Pyrrolopyrimidine derivatives useful in cancer treatment TP53, DPYD, CCNT1 PDGFRB 2700/4885PDPK1 947/4885RET 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.